MedPath

A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants

Phase 2
Completed
Conditions
Pneumococcal Infection
Registration Number
NCT03467984
Lead Sponsor
LG Chem
Brief Summary

The purpose of this study is to evaluate the safety and immunogenicity of LBVE (Multivalent Pneumococcal Conjugate Vaccine) in healthy infants.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
230
Inclusion Criteria
  • Healthy infants of either sex who have reached at least 42 days (6 weeks) of age and not more than 56 days (8 weeks) of age at the time of enrollment.
  • The parents or LAR(Legally authorized representative) able to understand and comply with planned study procedures.
  • Signed informed consent by subject's parents or LAR(Legally authorized representative)
Exclusion Criteria
  • Previously received any pneumococcal vaccine
  • Receipt of immunoglobulin or blood-derived product before the study
  • Known or suspected immune disorder, or received immunosuppressive therapy
  • Known major congenital malformation or serious chronic disorder
  • Participation in another interventional trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Proportion of subjects achieving pneumococcal serotype-specific IgG >= 0.35 ug/ml4 weeks after 3rd(last) vaccination
Pneumococcal serotype-specific IgG geometic mean concentration (GMC) ratios4 weeks after 3rd(last) vaccination
Secondary Outcome Measures
NameTimeMethod
Proportion of subjects achieving targeted pneumococcal serotype-specific opsonophagocytic assay (OPA) titer4 weeks after 3rd(last) vaccination
Unsolicited adverse eventsBaseline(pre-vaccination) up to 4 weeks after 3rd(last) vaccination
Solicited adverse eventsBaseline(pre-vaccination) up to 7 days after each vaccination
Pneumococcal serotype-specific OPA geometic mean titer (GMT) ratios4 weeks after 3rd(last) vaccination

Trial Locations

Locations (1)

LG chem

🇰🇷

Seoul, Gangseo-Gu, Korea, Republic of

LG chem
🇰🇷Seoul, Gangseo-Gu, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.